colorectal cancer charles lopez, m.d., ph.d. associate professor of medicine hematology and medical...
TRANSCRIPT
![Page 1: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/1.jpg)
COLORECTAL CANCER
Charles Lopez, M.D., Ph.D.
Associate Professor of Medicine
Hematology and Medical Oncology
May 2009
![Page 2: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/2.jpg)
Outline
• Background.
• Metastatic colorectal cancer.– Chemotherapeutic and biologic agents– Ongoing trials updates
• Adjuvant colorectal cancer.– Current practice and ongoing trials
![Page 3: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/3.jpg)
2007 Estimated US Cancer Cases*
ONS=Other nervous system.Source: American Cancer Society, 2007.
Men766,860
Women678,060 26% Breast
15% Lung & bronchus
11% Colon & rectum
6% Uterine corpus
4% Non-Hodgkin lymphoma
4% Melanoma of skin
4% Thyroid
3% Ovary
3% Kidney
3% Leukemia
21% All Other Sites
Prostate 29%
Lung & bronchus 15%
Colon & rectum 10%
Urinary bladder 7%
Non-Hodgkin4% lymphoma
Melanoma of skin 4%
Kidney 4%
Leukemia 3%
Oral cavity 3%
Pancreas 2%
All Other Sites 19%
COLORECTAL CANCER UPDATE
![Page 4: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/4.jpg)
* For those free of cancer at beginning of age interval. Based on cancer cases diagnosed during 2000 to 2002.Source: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.0 Statistical Research and Applications Branch, NCI, 2005. http://srab.cancer.gov/devcan
Lifetime Probability of Developing Cancer
WomenAll sites 1 in 2
Prostate 1 in 6
Lung 1 in 13
Colon and rectum 1 in 17
Urinary bladder 1 in 28
Lymphoma 1 in 46
Melanoma 1 in 52
Kidney 1 in 64
Leukemia 1 in 67
Oral Cavity 1 in 73
Stomach 1 in 82
All sites 1 in 3
Breast 1 in 8
Lung & bronchus 1 in 17
Colon & rectum 1 in 18
Uterine corpus 1 in 38
Lymphoma 1 in 55
Ovary 1 in 68
Melanoma 1 in 77
Pancreas 1 in 79
Urinary bladder 1 in 88
Uterine cervix 1 in 135
Men
COLORECTAL CANCER UPDATEEpidemiology
![Page 5: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/5.jpg)
Gastrointestinal Cancers in the United States
American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
Anus2%
Other digestive organs
2%
Small intestine2%
Gallbladder3%
Esophagus6%
Stomach8%
Pancreas13%
Colon41%
Rectum16%
Liver 7%
![Page 6: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/6.jpg)
Colorectal Cancer• Major public health problem in the US and
worldwide• Worldwide, nearly 1,000,000 cases diagnosed
each year• In the US, 130,000-140,000 cases diagnosed
each year. • In the US with 50,000-60,000 deaths each year < 40% of CRC diagnoses are localized disease
CRC = colorectal cancer.Colorectal Cancer Facts & Figures. 2005. American Cancer Society.
![Page 7: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/7.jpg)
Staging
I T1N0M0 A I T2N0M0 B1
IIA T3N0M0 B2 IIB T4N0M0 B3 IIIA T1-2N1M0 C1 IIIB T3-4N1M0 C2/C3 IIIC TanyN2M0 C1/C2/C3 IV TanyNanyM1 D
TNM Stage
TNM Class
MAC
(Modified Astler-Coller and New TNM Staging)
N2 denotes 4 or more regional lymph nodes (Need to sample at least 12 nodes).
![Page 8: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/8.jpg)
COLORECTAL CANCER UPDATEEpidemiology
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
Stage I
Stage II
Stage III
Stage IV
![Page 9: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/9.jpg)
Genetic susceptibility
FAP (risk approaches 100% by age 50)HNPCC (lifetime risk approaches 80%)
Family history Adenoma (first degree) RR 1.72;11% lifetime riskCRC (first degree) RR 2.62; 16% lifetime risk
Medical history Inflammatory bowel disease (pancolitis 8 years or left-sided colitis 15 years) (10-20% risk)
Characteristics Age (91% of cases occur after age 50)Male sex (35% in men)Race/ethnicity (15% in African Americans)Obesity and diet (red meat, alcohol consumption)Smoking
Risk Factors for Colorectal Cancer
FAP = familial adenomatous polyposis; HNPCC = hereditary nonpolyposis colon cancer syndrome; CRC = colorectal cancer.
Anderson FW, et al. J Natl Cancer Inst. 2002;94:1126-1133; Colorectal Cancer Facts & Figures. American Cancer Society; 2005; Levin B, et al. NCCN. v.1.2005; Lynch HT, et al. Cancer. 1995;76;2427-2433; Petersen GM, et al. Cancer. 1999;86(suppl):2540-2550; Winawer SJ, et al. Gastroenterology. 2003;124:544-560.
![Page 10: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/10.jpg)
Associations for Risk of Colorectal Cancer
Dietary Factors:Dietary FiberDietary FatRed MeatAlcohol FolateCalcium and vitamin D
Non-Dietary Factors:Body Mass IndexPhysical ActivityHormone replacementSmokingAspirin
• HPFS, middle age men: BMI 25 kg/m2;Physical activity 15 MET-hours/week;Daily folate containing MVI;Alcohol < 15 g/day;Non-smoker;Red meat 2 servings/week (e.g.-- 3.1% of all men)– Eliminate 71% of all colorectal cancer!
(95% CI, 33-92%)
![Page 11: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/11.jpg)
Colon Cancer: Multi-step Model of Carcinogenesis = biologic heterogeneity
• Cancers arise in polyps
• Develop over years• Multiple molecular events• Activation of oncogenes
and loss of tumor suppressor genes
Beart R. Clinical Oncology. Abeloff M, et al. Ed.Beart R. Clinical Oncology. Abeloff M, et al. Ed. 1998 Churchill Livingstone 1998 Churchill Livingstone
![Page 12: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/12.jpg)
Evolution of a lethal cancer
Jones S. et.al. PNAS 2008;105:4283-4288
©2008 by National Academy of Sciences
![Page 13: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/13.jpg)
By Denise Grady
An easily overlooked type of abnormality in the colon is the most likely type to turn cancerous, and is more common in this country than previously thought, researchers are reporting.
lity in the colon is the most likely type to turn cancerous, and is more common in this country than previously thought, researchers are reporting.
New York Times, March 5, 2008
COLORECTAL CANCER UPDATEScreening
Easily Overlooked Lesions Tied to Colon Cancer
![Page 14: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/14.jpg)
Flat Polyps
Soetinko et al. JAMA. 2008;299(9):1027-1035
COLORECTAL CANCER UPDATEScreening
![Page 15: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/15.jpg)
Flat Polyps
Soetinko et al. JAMA. 2008;299(9):1027-1035
COLORECTAL CANCER UPDATEScreening
![Page 16: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/16.jpg)
2000Irinotecan +
5-FU/LV (1st line)
2002Oxaliplatin + 5-FU/LV
(2nd line)
Development of Systemic Treatments for Metastatic Colorectal Cancer
19575-FU introduced
5-FU dominates treatment for mCRC
1996Irinotecan (2nd line)
1950 1960 1970 1980 1990 2000 2010
Investigations of 5-FU combination and schedules
2004 Oxaliplatin + 5-FU/LV
(1st line)
Targeted Therapies
2004Cetuximab
+ irinotecan (or alone)Bevacizumab + 5-FU-based
chemotherapy
5-FU = 5-fluorouracil; LV = leucovorin; mCRC = metastatic colorectal cancer.
Holen KD, Saltz LB. Lancet Oncol. 2001; 2:290-297; Venook A. The Oncologist. 2005;10:250-261.
Targeted regimens
Cytotoxic regimens
2006Panitumumab
![Page 17: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/17.jpg)
Therapeutic Regimens for the Treatment of MCRC
*Both first- and second-line exposure to therapy.
MCRC = metastatic CRC; OS = overall survival.Avastin® (bevacizumab) PI. December 2004.Camptosar® (irinotecan) PI. July 2005.Eloxatin™ (oxaliplatin) PI. April 2005.Erbitux™ (cetuximab) PI. June 2004.Xeloda® (capecitabine) PI. April 2003.Vectibix (panitumumab) PI. 2006.
Med
ian
OS
* (m
o)
0
6
12
18
24
~4-6
~12-14
~15-20
~15-17
~11-12
1980s 2000s1990s1960s5-FU
5-FU biomodulation
Irinotecan
Oxaliplatin
Cetuximab
Bevacizumab
Panitumumab
![Page 18: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/18.jpg)
Colorectal cancer:Evolution of 1st line therapy for metastatic
disease.
![Page 19: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/19.jpg)
5-Fluorouracil; 5-FU
![Page 20: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/20.jpg)
5-FU/LV Foundation.
U.S. Europe
bolus infusional
Mayomonthly
RoswellPark weekly
de Gramontbi-weekly
![Page 21: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/21.jpg)
First line: de Gramont vs Mayo 5-FU/LV
RR (%) PFS (wks) OS (mos)
500 pts randomized
5FU: 425mgs/m2 x5d, q 4wksLV: 20 mgs/m2 x5d, q 4wks
5FU: 400 mgs/m2(bolus) d1,2 q 2wksLV: 200 mgs/m2 d1,2 q 2wks5FU: 600 mgs/m2(22hrs) d1,2 q 2wks
40-
20-
33%
14%
8-
4-
27.622
p=0.0004 p=0.0012
14.1
13.1
p=0.06715-
13-
de Gramont et.al. JCO 15:808 (97).
![Page 22: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/22.jpg)
NH2
NH2
NH3C
O
O
C
O
Diaminocyclohexane(DACH) carrier ligand
CNH3
Cl
Cl
NH3
Pt
NH3
O
O
C
CISPLATINOXALATE
hydrolysable
ligand
trans-l-diaminocyclohexane
oxalatoplatinum
OXALIPLATIN, Eloxatin®CARBOPLATIN
Pt
Pt
O
O
Chemical Structure of Platinum Analogues
•Active in NCI CRC cell lines
•DNA adducts, cross-links
•Hold if CrCL<20cc/min
![Page 23: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/23.jpg)
RR (%) PFS (mos) OS (mos)
420 pts randomized
Oxaliplatin 85 mg/m2 d1, q 2wksLV: 200 mg/m2; 5FU 400mg/m2 IVB5FU 600 mg/m2 (22 hr CIV);d1,2q2wk
5FU: 400 mgs/m2(bolus) d1,2 q 2wksLV: 200 mgs/m2 d1,2 q 2wks5FU: 600 mgs/m2(22hrs) d1,2 q 2wks
50-
20-
51%
22%
10-
5-
9.0
6.2
p<0.0001 p=0.00116.2
14.7
p=0.1218-
14-
deGramont et.al. JCO 18:2938 (2000).
*
First line: FOLFOX vs infusional LV/5-FU
*=primary endpoint
#
#
![Page 24: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/24.jpg)
Irinotecan (CPT-11, Camptosar®)
Irinotecan hydrochloride
N NC
O
O N
N O
O
O
C 2H
O C 2H
C 3H
H C 3H
•Topoisomerase I inhibitor an enzyme that relieves torsional strain in DNA
•Hepatic metabolism. Majority excreted in bile requiring dose adjustment
•Converted by the carboxylesterase enzyme to the SN-38 metabolite, which is 1000-fold more potent than the parent drug
![Page 25: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/25.jpg)
First line: FOLFIRI vs infusional LV/5-FU
RR (%) PFS (mos) OS (mos)
385 pts randomized
CPT-11 180 mg/m2+ deGramont q 2wksor
CPT-11 80 mg/m2+HDLVB/5FU24CI qwk
deGramont q 2wksor
500 LVB/5FU 2600mg/m2 24 CIV qwk
40-
20-
35%
22%
8-
4-
6.74.4
p<0.005 p=0.001
17.4
14.1
p=0.03118-
14-
Douillard et.al. Lancet 355:1041 (2000).
![Page 26: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/26.jpg)
5-FU/LV Foundation.
U.S. Europe
bolus infusional
Mayomonthly
RoswellPark weekly
de Gramontbi-weekly
FOLFIRI FOLFOX
![Page 27: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/27.jpg)
5-FU/LV Foundation.
U.S. Europe
bolus infusional
Mayomonthly
RoswellPark weekly
de Gramontbi-weekly
FOLFIRI FOLFOXIFL
![Page 28: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/28.jpg)
First line: IFL vs Mayo 5-FU/LV
RR (%) PFS (mos) OS (mos)
457 pts randomized
5FU: 425mgs/m2 x5d, q 4wksLV: 20 mgs/m2 x5d, q 4wks
CPT11: 125 mgs/m2LV: 20 mgs/m25FU: 500 mgs/m2; q wk 4/6
40-
20-
39%
21%
8-
4-
7.0
4.3
p<0.001p=0.004 14.8
12.6
p=0.0415-
13-
Saltz et.al. NEJM 343:905 (2000).• 3rd arm: CPT-11 alone arm=LV/5FU
![Page 29: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/29.jpg)
5-FU/LV Foundation.
U.S. Europe
bolus infusional
Mayomonthly
RoswellPark weekly
de Gramontbi-weekly
FOLFIRI FOLFOXIFL
???
![Page 30: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/30.jpg)
RRAANNDDOOMMIIZZAATTIIOONN
CPT-11:CPT-11: 200 mg/m200 mg/m22 d1 q 3 wks d1 q 3 wksOxaliplatin:Oxaliplatin: 85 mg/m 85 mg/m22 d1 q 3 wks d1 q 3 wks
CPT-11:CPT-11: 125 mg/m125 mg/m22/wk x 4 wks, q 6 wks/wk x 4 wks, q 6 wks5FU:5FU: 500 mg/m500 mg/m22/wk x 4 wks, q 6 wks/wk x 4 wks, q 6 wks
LV:LV: 20 mg/m 20 mg/m22/wk x 4 wks, q 6 wks/wk x 4 wks, q 6 wks
Oxaliplatin:Oxaliplatin: 85 mg/m 85 mg/m22 d1 q 2 wks d1 q 2 wks5-FU:5-FU: 400 IV/600 CI mg/m400 IV/600 CI mg/m22 d1, 2 q 2 wks d1, 2 q 2 wks
LV:LV: 200 mg/m200 mg/m22 d1, 2 q 2 wks d1, 2 q 2 wks
Metastatic Metastatic Disease Disease Bolus Saltz Regimen*Bolus Saltz Regimen*
*Saltz *Saltz et alet al. . J Clin Oncol J Clin Oncol 14:2959, 1996. 14:2959, 1996.
Infusional FOLFOX-4 Regimen†Infusional FOLFOX-4 Regimen†
††André André et alet al. J Clin Oncol 17:3560, 1999. . J Clin Oncol 17:3560, 1999.
Wasserman Regimen‡Wasserman Regimen‡
‡‡Wasserman Wasserman et alet al. J Clin Oncol 17:1751, 1999.. J Clin Oncol 17:1751, 1999.
N=264N=264
N=267N=267
N=264N=264
Goldberg J Clin Oncol 22:23, 2004
First-Line Oxaliplatin in the US: N9741
Mayo
trash
IFL
FOLFOX4
IROX
![Page 31: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/31.jpg)
Europe vs USA?
Feb 2004: FOLFOX FDA approvedas first-line chemotherapy in U.S.
U.S.Euro
![Page 32: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/32.jpg)
N9741: Efficacy
IFL FOLFOX4 IROX
MS (mo) 14.8 19.5 17.4
TTP (mo) 6.9 8.7 6.5
ORR (%) 31 45 35
(p=0.001)
(p=0.0014)
(p=0.002)
Goldberg J Clin Oncol 22:23, 2004
(p=0.04)
FOLFOX: Second-line approval in US 8/02; First line approval 2/04
CPT-11:CPT-11: 200 mg/m200 mg/m22 d1 q 3 wks d1 q 3 wks
Oxaliplatin:Oxaliplatin: 85 mg/m 85 mg/m22 d1 q 3 wks d1 q 3 wks
N=264 N=267 N=264
![Page 33: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/33.jpg)
R
FOLFIRI FOLFOX6 progression
FOLFOX6 FOLFIRI progression
progression
progression
FOLFIRI versus FOLFOX
Regimens: oxaliplatin* (100 mg/m2) or irinotecan† (180 mg/m2) IV + LV 200 mg/m2 over 2 hours d 1, 5-FU 2,400-3,000 mg/m2 over 46 hours
Primary end point: TTPSecondary end points: ORR, safety
Tournigand et al. J Clin Oncol. 2004
N=113
N=113
![Page 34: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/34.jpg)
FOLFIRI verses FOLFOX6
Arm A Arm B
FOLFIRI FOLFOX FOLFOX FOLFIRI P
N=109 N=81 N=111 N=69 Value
ORR % 56* 15† 54* 4† .68
Median TTP (mo) 14.4 11.5 .65
Median Overall 20.4 21.5 .9Survival (mo
Tournigand C et al. JCO 2004
Results
(Similar results: Colucci G, et al. J Clin Oncol. 2005;23:4866-4875).
![Page 35: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/35.jpg)
Molecular re-classification of metastatic colorectal cancer
.
N
DIA HRN
I.
II. ?
?
![Page 36: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/36.jpg)
Molecular re-classification of metastatic colorectal cancer
.
N
DIA HRN
I.
II.Preliminary data: gene signature predicts diffuse
metastatic disease
![Page 37: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/37.jpg)
![Page 38: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/38.jpg)
Incorporation of Targeted Agents in the Standard Management of Metastatic Colorectal Cancer
![Page 39: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/39.jpg)
Agents Targeting the VEGF Pathway
VEGFR-2VEGFR-1PPP
P
Endothelial cell
Small-molecule VEGFR inhibitors
(TKIs)Ribozymes
Anti-VEGFR antibodies
Soluble VEGF
receptors
Anti-VEGF antibodies VEGF
PPP
P
–VEGF stimulates new blood vessel formation in normal tissues and tumors
–VEGF blockade normalizes tumor vasculature and improves drug delivery.
![Page 40: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/40.jpg)
Phase III Trial of Avastin + IFL as First-Line Therapy for MCRC (AVF2107g): OS
Error bars represent 95% CIs.Avastin® (bevacizumab) PI. December 2004.Data on file (SR2), Genentech, Inc. 2005.Hurwitz et al. N Engl J Med. 2004;350:2335.
100
OS
(%
)
Months
Median survival: 15.6 mo (w/o Avastin) vs 20.3 mo (w/Avastin)HR=0.66, P<0.001
1-year survival:74% vs 63%
2-year survival:45% vs 30%
20
00
80
40
60
6 12 18 24 30
Placebo + IFL (n=411)Avastin + IFL (n=402)
![Page 41: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/41.jpg)
EGFR as a Therapeutic Target
![Page 42: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/42.jpg)
The EGF Receptor: (HER1 or c-Erb-1)
EGF = epidermal growth factor; TGF- = transforming growth factor-alpha; EGFR = epidermal growth factor receptor.
EGF TGF-
EGFR EGFRHER2/3/4
EGFR
EGFR a member of a subfamily of type I receptor tyrosine kinases
(including HER2, HER3 and HER4)
![Page 43: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/43.jpg)
Properties of ERBITUX (Cetuximab) IgG1 MAb (chimerized) Binds specifically to EGFR
and its heterodimers Binds to EGFR with high affinity
(Kd = 2.0 x 10–10 M): 1 log higher than the natural ligand
Following the recommended doseregimen (400 mg/m2 initial dose/250 mg/m2 weekly dose), the mean half-life was 114 hours (range 75-188 hours)
ERBITUX Package Insert, June 2004; Data on file. ImClone Systems Incorporated and Bristol-Myers Squibb Company; 2004.
MAb = monoclonal antibody; EGFR = epidermal growth factor receptor.
Please see Important Safety Information including WARNING regarding infusion reactions on slides 39 to 52.
![Page 44: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/44.jpg)
Cetuximab activity in irinotecan refractory mCRC (Bond Trial): Objective Response Rates
All Patients
Irinotecan-Refractory and Oxaliplatin Failure Patients
Cunningham D, et al. N Engl J Med. 2004;351:337-345.
![Page 45: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/45.jpg)
ORR
8%
0%
• N=463• Patients
third-line mCRC
Panitumamab +BSC vs BSC
![Page 46: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/46.jpg)
NCIC-CO.17
mCRC failing (<6 months)
oxaliplatin and CPT11 regimens
with 5FU. No prior
anti-EGFR Rx. Bev permitted.
Primary endpoint=OS
Cetuximab+BSC
N=287
BSC
N=285
NOTE: No crossover allowed
Median duration of f/u = 14.6 months
Jonker et. al, NEJM 357:2040-08 (2007)
![Page 47: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/47.jpg)
OS
6.1 mo
4.6 mo
1 yr
21%
16%
p = 0.005
HR = .77
Cetuximab
plus bsc
Bsc alone
Primary endpoint
7% cross-over from bsc-->cet
Post trial rx: 27.5% (cet) verses 23.2% (bsc)
Jonker et. al, NEJM 357:2040-08 (2007)
![Page 48: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/48.jpg)
EPIC
mCRC failing
Oxaliplatin+/-bev
N=1298
CPT-11
+ cetuximab
CPT-11* Primary Endpoint = OS
50% crossover
Irinotecan: 350 mg/m2 q3weeks
Cetux: 400mg/m2 load then 250mg/m2
*OS
10.7 mo
9.99 mo
(p = ns)
PFS
3.98 mo
2.56 mo
(p < 0.0001)
RR
16.4%
4.1%
Sobrero et.al. AACR April 2007
What about in a “real world” setting?
![Page 49: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/49.jpg)
CRYSTAL
Untreated
mCRC
N=1217
FOLFIRI
+ Cetuximab
FOLFIRI
Primary Endpoint = PFS
PFS RR
8.9 mo
(34% 1yr)
8.0 mo
(23% 1yr)
p=0.036
46.9%
38.7%
p=0.005
Van Cutsem E, et al. ASCO 2007. Abstract 4000.
What about upfront?
![Page 50: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/50.jpg)
Metastatic colorectal cancer....
?
![Page 51: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/51.jpg)
CALGB/SWOG80405 Trial: First Line Met CRC.
FOLFOX
FOLFIRI
Bev
C225
Bev/C225
“Dea
lers
Cho
ice”
Ran
dom
ize
Su r
g eo n
s in
v olv
ed e
n ti r
e w
a y
Study PIs: Charles Blanke, M.D./Alan Venook, M.D.
Target accrual 2300
![Page 52: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/52.jpg)
PACCE: Panitumumab Advanced CRC Evaluation Study
RANDOMIZE
Panitumumab + oxaliplatin- or irinotecan-based chemotherapy + bevacizumab
(q2 wk) • First-line mCRC
• No CNS metastases
• No CV risk factors
Oxaliplatin- or irinotecan-based chemotherapy + bevacizumab
(q2 wk)
US NIH Clinical Trials Database (www.clinicaltrials.gov); accessed 8/3/06
Primary endpoint=PFSN >1000
Interim (12-week) response-rate analysis first 500 patients:
response rates similar between treatment groups.
![Page 53: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/53.jpg)
Cairo 2
mCRC
Capox + bev + cetux
Capox + bev
PFS tox
N=368
N=368
9.6 mo
10.7 mo
p=0.018
82%
72%
p=0.0013
Punt et. al ASCO 2008
![Page 54: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/54.jpg)
Cairo 2
mCRC
Capox + bev + cetux
Capox + bev
PFS
N=368
N=368
9.6 mo
10.7 mo
p=0.018
Punt et. al ASCO 2008
PFSWT-KRAS
PFSMT-KRAS
10.5 mo
10.5 mo
8.6 mo
12.5 mo
p<0.05p=ns
![Page 55: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/55.jpg)
CRYSTAL
Untreated
mCRC
N=1217
FOLFIRI
+ Cetuximab
FOLFIRI
10Endpoint = PFS
PFS
8.9 mo
(34% 1yr)
8.0 mo
(23% 1yr)
p=0.036
Van Cutsem E, et al. ASCO 2008.
PFS
WT-KRAS
9.9 mo
(43% 1yr)
8.6 mo
(25% 1yr)
p=0.017
PFS
MT-KRAS
p=0.75HR=0.85 HR=0.68 HR=1/07
No change in PFS or RR in FOLFIRI w/o cetuximab
Suggests KRAS a predictive marker (vs prognostic)
OPUS trial: randomized phase II FOLFOX +/- cetuximab similar results that only
WT-KRAS benefits from cetuximab (Bokemeyer et. al. ASCO 2008)
![Page 56: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/56.jpg)
Metastatic colorectal cancer....
??????
![Page 57: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/57.jpg)
The EGF Receptor: (HER1 or c-Erb-1)
EGF = epidermal growth factor; TGF- = transforming growth factor-alpha; EGFR = epidermal growth factor receptor.
EGF TGF-
EGFR EGFRHER2/3/4
EGFR
EGFR a member of a subfamily of type I receptor tyrosine kinases
(including HER2, HER3 and HER4)
![Page 58: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/58.jpg)
CALGB/SWOG80405 Trial: First Line Met CRC.
FOLFOX
FOLFIRI
Bev
C225
Bev/C225
“Dea
lers
Cho
ice”
Ran
dom
ize
Su r
g eo n
s in
v olv
ed e
n ti r
e w
a y
Study PIs: Charles Blanke, M.D./Alan Venook, M.D.
Target accrual 2300
ONLY WT KRAS
![Page 59: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/59.jpg)
![Page 60: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/60.jpg)
![Page 61: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/61.jpg)
ADJUVANT THERAPY
I T1N0M0 A I T2N0M0 B1
IIA T3N0M0 B2 IIB T4N0M0 B3 IIIA T1-2N1M0 C1 IIIB T3-4N1M0 C2/C3 IIIC TanyN2M0 C1/C2/C3 IV TanyNanyM1 D
TNM Stage
TNM Class
MAC
?
(Modified Astler-Coller and New TNM Staging)
?
N2 denotes 4 or more regional lymph nodes (Need to sample at least 12 nodes).
![Page 62: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/62.jpg)
Zollinger, Atlas of Surgical Operations, 1993
COLORECTAL CANCER UPDATESurgical Management
![Page 63: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/63.jpg)
COLORECTAL CANCER UPDATESurgical Management
![Page 64: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/64.jpg)
Total Mesorectal Excision• nerve preservation
• sharp dissection
• complete hemostasis
• intact mesorectal envelope.
COLORECTAL CANCER UPDATESurgical Management
![Page 65: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/65.jpg)
Revised, node-positive TNM classification for Stage III CRC (n=50,042)
59.8%59.8%
42.0%42.0%
27.3%27.3%
00
1010
2020
3030
4040
5050
6060
7070
IIIAIIIA IIIBIIIB IIICIIIC
Node-positive subgroupsNode-positive subgroups
Observed 5-year Observed 5-year survival (%)survival (%)
p<0.0001p<0.0001
IIIA: T1/2, N1IIIA: T1/2, N1 IIIB: T3/4, N1IIIB: T3/4, N1 IIIC: Any T, N2IIIC: Any T, N2
Greene Greene et alet al (2002) (2002)
![Page 66: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/66.jpg)
Adjuvant Therapy for Stage II Colon Cancer:
• ASCO Guidelines : 8/15/04 JCO– “Pts with high risk features..might be considered candidates for adjuvant
therapy..” BUT,– “Direct evidence does not support adjuvant chemotherapy..even for high
risk stage II..”
• http://www.mayoclinic.com/calcs/colon/index-ccacalc.cfm
• Estimate that Stage II trials will need >8000 patients to provide direct evidence for benefit.• Need: better risk stratification to identify patient subgroups that will benefit (e.g. do-able trials).
![Page 67: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/67.jpg)
Adjuvant Therapy for Stage II Colon Cancer
• Indirect evidence makes it reasonable to offer for patients with high risk features who are willing to accept toxicity for theoretical benefit.– High risk features:
• < 12 LN sampled• Obstruction at presentation• Perforation at tumor site• High grade tumor• LVI
• Should encourage participation in randomized trials.
![Page 68: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/68.jpg)
MOSAIC: Treatment arms
R
LV5FU2(n=1123)
FOLFOX4(n=1123)
Primary: – 3-yr Disease Free Survival (DFS): a
surrogate for 5-yr Survival Secondary:
– Safety – Overall Survival (OS)
Endpoints
Resected Stage II/III CRC
N=2246
40% Stage II
60% Stage III
NEJM 350(23):2343, 2004
![Page 69: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/69.jpg)
MOSAICStage III
1.0
0.9
0.8
0.7
0.6
0.50 10 20 30 40 50
24% risk reduction for stage III patients in the FOLFOX4 arm
DFS (months)
4-year DFS
FOLFOX4 (n=672) 70%LV5FU2 (n=675) 61%
p=0.002
Pro
bab
ilit
y
Improved 6 year overall survival for Stage III
(hazard ratio of 0.80, confidence interval [0.65, 0.97], p=0.023).
![Page 70: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/70.jpg)
Phase III MOSAIC Trial (ITT): Clinical Efficacy
Disease-freesurvival (DFS) FOLFOX
LV/5-FU2
Overall 76% 69%p=0.0008
risk reduction 24%
Stage III 70% 61% p=0.002
Stage II 86.6% 83.9% p-value not significant
de Gramont A, et al. Proc Am Soc Clin Oncol. 2003 Abstr 1015; Andre et.al NEJM 6/04
![Page 71: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/71.jpg)
Irinotecan Negative in Adjuvant Setting
Clinical Trial Patients Outcome
CALGB C89803
(IFL vs FL)
Stage III
(n=1264)
More neutropenia, death
PETACC-3(FOLFIRI vs deGramont)
Stage II/III
(n=3278)
More neutropenia, diarrhea
ACCORD02(LV5FU2+/-CPT11
High-risk Stage III
(n=400)
More neutropenia,
nausea
Saltz et.al ASCO Ab 3500 (2004)
Van Cutsem et.al ASCO Ab 8 (2005)
Ychou et.al. Ab 3502 ASCO (2005)
![Page 72: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/72.jpg)
Molecular re-classification of metastatic colorectal cancer
.
N
DIA HRN
I.
II. ?
?
![Page 73: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/73.jpg)
Potentially resectable
mCRC
No extrahepatic disease
≤4 lesions
No prior Rx
Primary endpoint
– 40% increase in PFS
(NOT designed to validate
Pre vs post-op chemo)
EORTC 40983
Nordlinger, ASCO 2007
FOLFOX x6
Surgery
FOLFOX x6
N=182
Surgery
N=182
3 yr PFS
35.4%
28.1%
P=0.058
All pts Eligilble pts
36.2%
28.1%
P=0.041
![Page 74: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/74.jpg)
EORTC 40983
• More postoperative complications in FOLFOX group 25% vs. 16% (p=0.04). (e.g. liver failure, biliary fistula).
• No difference in postoperative mortality
Nordlinger, ASCO 2007
![Page 75: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/75.jpg)
Adjuvant colorectal cancer
1. FOLFOX for stage III (MOSAIC). -NSABPC07 (bolus 5FU+/- ox) confirms MOSAIC. FLOX with
unfavorable toxicity profile?
2. No direct evidence for stage II pts. But, indirect evidence makes reasonable to discuss if high risk features
• < 12 LN sampled• Obstruction at presentation• Perforation at tumor site• High grade tumor• LVI
![Page 76: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/76.jpg)
Some ongoing adjuvant trials
![Page 77: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/77.jpg)
Stage II CRC: E5202 Intergroup Trial
Stage IIStage IIpatientspatients
MSSMSSLOH 18qLOH 18q
MSI+MSI+normal 18qnormal 18q
RRFOLFOXFOLFOX
FOLFOX +FOLFOX +bevacizumabbevacizumab
No therapyNo therapy
Accrual goal: 3,125
![Page 78: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/78.jpg)
NSABP C-08: mFOLFOX6 + Bevacizumab
RANDOMIZE
mFOLFOX6 + Bevacizumab
q14 d for 12 courses• Patients with resected stage II/III colon cancer
• Target enrollment, 2632
mFOLFOX6q14 d for 12 courses
Trial opened Sept 2004.
Bevacizumabq14 d for 6 mo(in absence of
PD)
US NIH Clinical Trials Database (www.clinicaltrials.gov); accessed 8/3/06.
ASCO 2008 Safety Update: increased grade III toxicity, p=0.006
![Page 79: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/79.jpg)
AVANT Trial: FOLFOX vs FOLFOX/BEV vs XELOX/BEV
RANDOMIZE
FOLFOX4
• Patients with stage II/III colon cancer
• Target enrollment, 3450
FOLFOX4 + Bevacizumab
XELOX + Bevacizumab
US NIH Clinical Trials Database (www.clinicaltrials.gov); accessed 8/21/06.
?????????????
![Page 80: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/80.jpg)
N0147: Adjuvant Cetuximab
RANDOMIZE
FOLFOX4 ± Cetuximab
• Patients with resected stage III colon cancer
• Target enrollment, 2300
(FOLFOX then FOLFIRI) ± Cetuximab
FOLFIRI ± Cetuximab
US NIH Clinical Trials Database (www.clinicaltrials.gov); accessed 8/3/06.
For WT-KRAS ONLY!!!!!!!!
![Page 81: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/81.jpg)
Reality Check......
• Cost: Shrag, NEJM, 7/2004– Average patient with 1st line FOLFOX+ bevacizumab (8 months)
followed by CPT-11 + cetuximab (4 months)=$161,000 USD X 50,000 Stage IV cases/year
– > $5 BILLION USD /year (JUST for stage IV..if used for adjuvant..> $20 BILLION USD/year!!!!
– How do we save $$$?• Lower cost• Limit therapy (per group)• Individualize treatments to those most likely to benefit (per
patient)• Limit duration of therapy
![Page 82: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/82.jpg)
![Page 83: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/83.jpg)
Colon Cancer: Multi-step Model of Carcinogenesis = biologic heterogeneity
• Cancers arise in polyps
• Develop over years• Multiple molecular events• Activation of oncogenes
and loss of tumor suppressor genes
Beart R. Clinical Oncology. Abeloff M, et al. Ed.Beart R. Clinical Oncology. Abeloff M, et al. Ed. 1998 Churchill Livingstone 1998 Churchill Livingstone
![Page 84: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/84.jpg)
The Genomic Landscapes of Human Breast and CRC Cancers
Wood et al. Science 2007;318:1108-13.
Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes.
To catalog the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11
colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples.
Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the
genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene "mountains"
and a much larger number of gene "hills" that are mutated at low frequency. We describe statistical and
bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications
for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.
![Page 85: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/85.jpg)
Current
patients
A
B
All patients receive standard treatment (A)
Clinical trials survival benefit from A
Future
patients Molecular analysis of tumor
AA
BB
CC
DD
Choice of treatmentdependent upon molecular profile of tumor andpatient genotype
A New Paradigm for Colorectal Cancer A New Paradigm for Colorectal Cancer Clinical TrialsClinical Trials
A New Paradigm for Colorectal Cancer A New Paradigm for Colorectal Cancer Clinical TrialsClinical Trials
![Page 86: COLORECTAL CANCER Charles Lopez, M.D., Ph.D. Associate Professor of Medicine Hematology and Medical Oncology May 2009](https://reader035.vdocument.in/reader035/viewer/2022081506/56649d885503460f94a6da49/html5/thumbnails/86.jpg)
Stay tuned for upcoming exciting info...........